Literature DB >> 23454269

A cell-penetrating peptide suppresses the hypoxia inducible factor-1 function by binding to the helix-loop-helix domain of the aryl hydrocarbon receptor nuclear translocator.

Yu Wang1, John D Thompson, William K Chan.   

Abstract

The heterodimeric hypoxia inducible factor-1 (HIF-1) complex is composed of the hypoxia inducible factor-1 alpha (HIF-1α) and the aryl hydrocarbon receptor nuclear translocator (ARNT). Activation of the HIF-1 function is essential for tumor growth and metastasis. We previously showed that transfection of a plasmid containing an ARNT-interacting peptide (Ainp1) cDNA suppresses the HIF-1 signaling in Hep3B cells. Here we generated TAT fusion of the Ainp1 peptide (6His-TAT-Ainp1) to determine whether and how the Ainp1 peptide suppresses the HIF-1 function. The bacterially expressed 6His-TAT-Ainp1 was purified under denatured condition and then refolded by limited dialysis. The refolded 6His-TAT-Ainp1 interacts with the helix-loop-helix (HLH) domain of ARNT in a similar fashion as the native 6His-Ainp1. 6His-TAT-Ainp1 colocalizes with ARNT in the nucleus of HeLa and Hep3B cells after protein transduction. The transduced protein reaches the maximum intracellular levels within 2 h while remains detectable up to 96 h in HeLa cells. At 2 μM concentration, 6His-TAT-Ainp1 is not cytotoxic in HeLa cells but suppresses the cobalt chloride-activated, hypoxia responsive enhancer-driven luciferase expression in a dose-dependent manner. In addition, it decreases the cobalt chloride-dependent induction of the HIF-1 target genes at both the message (vascular endothelial growth factor and aldolase C) and protein (carbonic anhydrase IX and glucose transporter 1) levels. The protein levels of HIF-1α and ARNT are not altered in the presence of 6His-TAT-Ainp1. In summary, we provided evidence to support that the Ainp1 peptide directly suppresses the HIF-1 function by interacting with the ARNT HLH domain, and in turn interfering with the heterodimerization of HIF-1α and ARNT.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454269      PMCID: PMC3661001          DOI: 10.1016/j.cbi.2013.02.003

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  39 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs.

Authors:  Y Okazaki; M Furuno; T Kasukawa; J Adachi; H Bono; S Kondo; I Nikaido; N Osato; R Saito; H Suzuki; I Yamanaka; H Kiyosawa; K Yagi; Y Tomaru; Y Hasegawa; A Nogami; C Schönbach; T Gojobori; R Baldarelli; D P Hill; C Bult; D A Hume; J Quackenbush; L M Schriml; A Kanapin; H Matsuda; S Batalov; K W Beisel; J A Blake; D Bradt; V Brusic; C Chothia; L E Corbani; S Cousins; E Dalla; T A Dragani; C F Fletcher; A Forrest; K S Frazer; T Gaasterland; M Gariboldi; C Gissi; A Godzik; J Gough; S Grimmond; S Gustincich; N Hirokawa; I J Jackson; E D Jarvis; A Kanai; H Kawaji; Y Kawasawa; R M Kedzierski; B L King; A Konagaya; I V Kurochkin; Y Lee; B Lenhard; P A Lyons; D R Maglott; L Maltais; L Marchionni; L McKenzie; H Miki; T Nagashima; K Numata; T Okido; W J Pavan; G Pertea; G Pesole; N Petrovsky; R Pillai; J U Pontius; D Qi; S Ramachandran; T Ravasi; J C Reed; D J Reed; J Reid; B Z Ring; M Ringwald; A Sandelin; C Schneider; C A M Semple; M Setou; K Shimada; R Sultana; Y Takenaka; M S Taylor; R D Teasdale; M Tomita; R Verardo; L Wagner; C Wahlestedt; Y Wang; Y Watanabe; C Wells; L G Wilming; A Wynshaw-Boris; M Yanagisawa; I Yang; L Yang; Z Yuan; M Zavolan; Y Zhu; A Zimmer; P Carninci; N Hayatsu; T Hirozane-Kishikawa; H Konno; M Nakamura; N Sakazume; K Sato; T Shiraki; K Waki; J Kawai; K Aizawa; T Arakawa; S Fukuda; A Hara; W Hashizume; K Imotani; Y Ishii; M Itoh; I Kagawa; A Miyazaki; K Sakai; D Sasaki; K Shibata; A Shinagawa; A Yasunishi; M Yoshino; R Waterston; E S Lander; J Rogers; E Birney; Y Hayashizaki
Journal:  Nature       Date:  2002-12-05       Impact factor: 49.962

3.  A functional rhodopsin-green fluorescent protein fusion protein localizes correctly in transgenic Xenopus laevis retinal rods and is expressed in a time-dependent pattern.

Authors:  O L Moritz; B M Tam; D S Papermaster; T Nakayama
Journal:  J Biol Chem       Date:  2001-05-11       Impact factor: 5.157

Review 4.  Peptide-mediated cell delivery: application in protein target validation.

Authors:  Mark A Lindsay
Journal:  Curr Opin Pharmacol       Date:  2002-10       Impact factor: 5.547

Review 5.  Phage display-derived peptides as therapeutic alternatives to antibodies.

Authors:  Robert C Ladner; Aaron K Sato; Jennifer Gorzelany; Mark de Souza
Journal:  Drug Discov Today       Date:  2004-06-15       Impact factor: 7.851

6.  Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia.

Authors:  Nobuhito Goda; Heather E Ryan; Bahram Khadivi; Wayne McNulty; Robert C Rickert; Randall S Johnson
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

7.  Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1.

Authors:  B H Jiang; E Rue; G L Wang; R Roe; G L Semenza
Journal:  J Biol Chem       Date:  1996-07-26       Impact factor: 5.157

8.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis.

Authors:  Jehangir S Wadia; Radu V Stan; Steven F Dowdy
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

Review 9.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 10.  Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

Authors:  Allan J Pantuck; Gang Zeng; Arie S Belldegrun; Robert A Figlin
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  6 in total

1.  Differential suppression of the aryl hydrocarbon receptor nuclear translocator-dependent function by an aryl hydrocarbon receptor PAS-A-derived inhibitory molecule.

Authors:  Jinghang Xie; Xin Huang; Miki S Park; Hang M Pham; William K Chan
Journal:  Biochem Pharmacol       Date:  2014-01-28       Impact factor: 5.858

2.  Cell-penetrable mouse forkhead box protein 3 alleviates experimental arthritis in mice by up-regulating regulatory T cells.

Authors:  Xia Liu; Baoju Ji; Mengyi Sun; Weijiang Wu; Lili Huang; Aihua Sun; Yangyong Zong; Sheng Xia; Liyun Shi; Hui Qian; Wenrong Xu; Qixiang Shao
Journal:  Clin Exp Immunol       Date:  2015-05-10       Impact factor: 4.330

3.  Cell penetrable-mouse forkhead box P3 suppresses type 1 T helper cell-mediated immunity in a murine model of delayed-type hypersensitivity.

Authors:  Xia Liu; Jun Wang; Hui Wang; Chen Zhou; Qihong Yu; Lei Yin; Weijiang Wu; Sheng Xia; Qixiang Shao
Journal:  Exp Ther Med       Date:  2017-01-02       Impact factor: 2.447

Review 4.  Specific Inhibition of HIF Activity: Can Peptides Lead the Way?

Authors:  Ilias Mylonis; Georgia Chachami; George Simos
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

Review 5.  Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target.

Authors:  Vittoria Infantino; Anna Santarsiero; Paolo Convertini; Simona Todisco; Vito Iacobazzi
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

6.  The expression level of the transcription factor Aryl hydrocarbon receptor nuclear translocator (ARNT) determines cellular survival after radiation treatment.

Authors:  Markus Mandl; Maria- Katharina Lieberum; Juergen Dunst; Reinhard Depping
Journal:  Radiat Oncol       Date:  2015-11-16       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.